Sugi Predict

Sugi Predict / Compounds / SCHEMBL4249233

SCHEMBL4249233

SCHEMBL4249233

CC(C)(C)c1cc2nc(N)ccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 6/20 0.38
▸ NCK1 P16333 1/20 0.38
▸ PLAU P00749 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ NCF1 P14598 2/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ SCN10A Q9Y5Y9 1/20 0.35
▸ F7 P08709 2/20 0.34
▸ NOS2 P35228 1/20 0.34
▸ FABP6 P51161 1/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ KEAP1 Q14145 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ PARP1 P09874 1/20 0.33
▸ MASP2 O00187 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NUDT1 P36639 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4248284 0.82 SIRT2 (0.37) KCNH2SCN10AALDH1A1LMNA
SCHEMBL26262624 0.80 CYP1A2 (0.38) KCNH2SCN10ANOS2ALDH1A1LMNA
SCHEMBL19663767 0.80 ALDH1A1 (0.35) KCNH2SCN10AALDH1A1LMNAMEN1
SCHEMBL15431204 0.79 CYP2A6 (0.50) BACE1NCK1PLAUADORA2AADORA1
SCHEMBL26262615 0.79 LMNA (0.34) KCNH2SCN10AALDH1A1LMNA
SCHEMBL26262609 0.79 ALDH1A1 (0.34) KCNH2SCN10AALDH1A1LMNAMEN1
Hydrochloric Acid SCHEMBL31715333 0.78 CYP2A6 (0.48) BACE1NCK1PLAUADORA2AADORA1
Hydrochloric Acid SCHEMBL21873980 0.78 CYP2A6 (0.48) BACE1NCK1PLAUADORA2AADORA1
SCHEMBL26265751 0.76 MAPT (0.36) ALDH1A1LMNAMEN1KMT2A
SCHEMBL24976098 0.72 PLAU (0.39) BACE1NCK1PLAUADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-11661418-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-05-30 — — US disclosed
US-11661418-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-05-30 — — US disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 — — US disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 — — US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 — — US disclosed
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-17 — — US disclosed
US-20140024672-A1 AZAINDOLE DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-23 — — US disclosed
US-8563573-B2 Azaindole derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-22 — — US disclosed
US-8563573-B2 Azaindole derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-22 — — US disclosed
US-8563573-B2 Azaindole derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-22 — — US disclosed
EP-2118103-A2 AZAINDOLE DERIVATIVES AS CFTR MODULATORS Vertex Pharmaceuticals Incorporated (US) 2009-11-18 — — EP disclosed
US-20090253736-A1 AZAINDOLE DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-08 — — US disclosed
US-20090253736-A1 AZAINDOLE DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-08 — — US disclosed
US-20090253736-A1 AZAINDOLE DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-08 — — US disclosed
WO-2008127399-A2 AZAINDOLE DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-10-23 — — WO disclosed
WO-2008127399-A2 AZAINDOLE DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 BACE1 2275/4885NCK1 1099/4885PLAU 301/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 BACE1 2314/4885NCK1 1111/4885PLAU 303/4885
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 BACE1 2275/4885NCK1 1099/4885PLAU 301/4885
US-20140024672-A1 AZAINDOLE DERIVATIVES AS CFTR MODULATORS CFTR, ABCB1, ABCC2 BACE1 4037/4885NCK1 1936/4885PLAU 4751/4885
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 BACE1 2314/4885NCK1 1111/4885PLAU 303/4885
US-20090253736-A1 AZAINDOLE DERIVATIVES AS CFTR MODULATORS CFTR, ABCB1, ABCC2 BACE1 4037/4885NCK1 1936/4885PLAU 4751/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 BACE1 2314/4885NCK1 1111/4885PLAU 303/4885
US-11661418-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 BACE1 2314/4885NCK1 1111/4885PLAU 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.